Prescription drug sales projected to jump 62% to €1.7 trillion, driven by obesity and autoimmune therapies
Executive summary: Expansión reported that prescription drug sales are expected to grow 62% to about 1.7 trillion euros. This growth signals a major expansion of the pharmaceutical market, especially in obesity and autoimmune therapies, influencing revenue forecasts for major drug makers.
Who is involved: Key players mentioned include Eli Lilly (with its obesity drugs Mounjaro, Zepbound and Foundayo) and unspecified makers of leading autoimmune treatments.
Likely next: By 2032, obesity drugs are projected to constitute roughly half of the sales of the top ten prescription medicines, prompting further investment and potential pricing scrutiny.
According to Expansión, global prescription drug sales are forecast to rise 62% reaching approximately 1.7 trillion euros by 20 by 2032. The report highlights that obesity treatments such as Lilly’s Mounjaro, Zepbound and the upcoming Foundayo will account for nearly half of the spending on the ten best‑selling medicines, with autoimmune drugs following as the next major growth area of growth. The report highlights that obesity treatments such as Lilly’s Mounjaro, Zepbound and the upcoming Foundayo will account for nearly half of the spending on the ten best‑selling medicines, with autoimmune drugs following as the next major growth area. The projection underscores a shift in therapeutic focus toward metabolic and immune‑mediated conditions. No contradictory figures were presented in the source.
Timeline
- — Las ventas de fármacos con receta crecerán un 62%, hasta 1,7 billones (Expansión)
Analysis — what this means
Likely next events
- By 2032, obesity drugs (Mounjaro, Zepbound, Foundayo) are forecast to account for nearly 50% of the sales of the ten best‑selling prescription medicines.
Sectors affected
- Obesity drug market
- Autoimmune drug market
Sources
Related cases
- Spain's video game market generated €2.29 billion in 2025, marking over 30% growth in five years and underscoring the sector's expanding role in the country's digital entertainment economy
- Expansión opinion piece flags broader symptoms of Spain's housing crisis, linking affordability, construction costs and macro‑financial risks
- Effective one‑on‑one meetings drive employee performance by being frequent, brief and action‑oriented
- UK launch of oral diabetes pill Foundayo signals new competition in weight‑loss drug market
- European banks boost synthetic risk transfer volumes to €378 bn in 2025, up 170% in four years
- Expansión warns that declining civil society and rising polarization threaten social cohesion and, by extension, the stability of the business environment